Read on Twitter
#TCTM21 Plenary: Leukemia: Drugs to Decrease Relapse Dr DiNardo @LeukemiaMDA
AML prognosis depends on genetics, nice treatment algorithm
Core-binding factor AML (inv (16) or t (8,21) : GO added to intensive chemo
AML prognosis depends on genetics, nice treatment algorithm Core-binding factor AML (inv (16) or t (8,21) : GO added to intensive chemo
#TCTM21 FLT-3
Adverse mutation,more in younger pts
Phase I 7+3+ Gilteritinib: CRc ~81%
SORMAIN: post transplant sorafenib maintenance: Improvement in 2-yr RFS with increased AEs
ADMIRAL pts who resumed Gilteritinib after transplant had better median OS (16.2vs 8.4 mo)
Adverse mutation,more in younger ptsPhase I 7+3+ Gilteritinib: CRc ~81% SORMAIN: post transplant sorafenib maintenance: Improvement in 2-yr RFS with increased AEsADMIRAL pts who resumed Gilteritinib after transplant had better median OS (16.2vs 8.4 mo)
#TCTM21 Other mutations
Phase I of 7+3+ IDHi showed good responses (Phase III is recruiting)
tAML CPX prolonged follow up data
Phase I of 7+3+ IDHi showed good responses (Phase III is recruiting) tAML CPX prolonged follow up data
#TCTM21
MRD role is vital but not clear what to do with +ve MRD
FLAG-IDA + venetoclax maybe helpful to get more patients into transplant
MRD role is vital but not clear what to do with +ve MRDFLAG-IDA + venetoclax maybe helpful to get more patients into transplant
